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Abstract. Through all the immediate and long-term consequences of estrogenic deprivation, menopause is an important 
public health issue with social, personal and economic impact. If immediate menopausal symptoms are sometimes noisy, 
the long-term, insidious consequences, especially cardiovascular and bone, are of major importance. In order to eliminate 
troublesome symptoms and prevent long-term consequences in order to provide a good quality of life for menopausal 
women, it is nowadays unanimously recognized that hormonal therapy is necessary in the context of adhering to 




Menopause, by modifying the hormonal profile (mainly by lowering estrogen hormones), is a risk factor in the development 
of atherosclerosis. Endothelial dysfunction plays a key role both in the pre-lesional and lesional stages of atherosclerosis 
(Atsma, F., et al, 2006; Al-Azzawi, F. & Palacios, S., 2009). 
Endothelial dysfunction induced by dyslipidemia, especially oxidized LDL, is the first step in the initiation and evolution 
of the atherogenic process (Kalantaridou, S.N., et al, 2006). 
When reaching menopause, women are prone to fluctuations of estrogen that can lead to dyslipidemia (with increased 
triglycerides, total serum cholesterol, LDL cholesterol, and lower HDL cholesterol) (Crauciuec, E., et al, 2006; Acken, 
H.S. Jr, 2000). The decrease in estrogen in the menopause leads to a change in the lipid profile, with increases in 
triglycerides, total serum cholesterol, LDL cholesterol and lower HDL cholesterol (with an antiatherogenic protective 
role) (Bădoi, D., 2012).  
Studies have already shown that in the natural and surgical menopause the atherosclerotic process is based on endothelial 
damage caused by altered lipid metabolism. Hormonal treatment, mainly by ingesting estrogen, positively influences lipid 
metabolism and thereby decreases the risk of cardiovascular disease (Atsma, F., 2006; Knowlton, A.A., 2012). 
With all the immediate and long-term consequences of estrogenic deprivation, menopause is an important public health 
issue with social, personal and economic impact. If immediate menopausal symptoms are sometimes noisy, the long-term, 
insidious consequences, especially cardiovascular and bone, are of major importance.  
In order to eliminate troublesome symptoms and prevent long-term consequences, in order to provide a good quality of 
life for women in menopause, it is nowadays unanimously recognized that hormonal therapy is necessary in the context of 
respecting some recognized indications and contraindications and in the rigorous following of the therapy effects. 
One of the main objectives of the clinical trial was to evaluate the lipid and carbohydrate profile in natural menopause 
and the effects of hormonal therapy. The evolution of climacteric symptomatology under treatment was also observed. 
 
MATERIAL AND METHOD 
 
In order to conduct the clinical study, we used the extended database of menopausal patients belonging to the Third Clinic 
of Obstetrics-Gynecology from "Elena Doamna" Hospital Iaşi and "Medical Life" Obstetrics-Gynecology Practice Iaşi, a 
database that records the menopausal patients from all over Moldova for over 15 years. Every patient recorded in the 
database has a medical chart containing almost 30 indicators; from this database we can extract what we are interested in, 
namely phytoestrogens and their effects for a certain period; this is how the three lots, the study period, the inclusion and 
exclusion criteria, the statistical study and the results were established. 
Study groups. We studied the patients in natural menopause in 2016, ie 83 patients with anamnestic amenorrhea for at 
least 1 year, divided into the following study groups: 
Lot I       - 37 patients with natural menopause treated with Activelle (1 mg estradiol + 0.5 mg norethisterone 
acetate); 
Lot II      - 22 patients with natural menopause fed with natural phytoestrogens; 
Lot III    - 24 patients in untreated natural menopause. 
The inclusion criteria were as follows: 
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- anamnestic amenorrhoea for at least 1 year; 
- absence of hormonal treatment at least for 1 year. 
The clinical and paraclinical evolution of the patients was followed. Each patient had a form filled with information 
about: age, residence, smoking, alcohol consumption, anthropometric data, heredo-collateral history, personal 
physiological and pathological priors, onset of menopause, previous hormonal treatments, clinical symptomatology, 
paraclinical assessment, type of treatment in menopause. 
At the onset of the study the presence of climacteric symptoms was assessed and we performed the following: 
- measuring waist, weight, blood pressure; 
- complete clinical and genital examination; 
- Babeş - Papanicolau cytological smear; 
- ultrasound for measuring the thickness of the endometrium; 
- evaluation of lipid metabolism parameters: total serum cholesterol, triglycerides, LDL cholesterol, HDL 
cholesterol; 
- blood glucose, TGP, hemoglobin; 
- EKG; 
- mammography and osteodensitometry. 
Biochemical determinations used serum obtained after blood collection in "activator clot" tubes and centrifugation at 
4000 rpm for 10 minutes. An automated clinical chemistry analyzer, RX Imola model, with the use of calibrators and 
control serum, was used to determine the biochemical parameters. 
Hormonal estrogen therapy 
Estrogen administration is the main way to treat menopause (Bădoi, D., 2012). 
Classification of estrogen types: 
 natural: 
          - estrone; estriol; 
          - 17-β estradiol; 
          - estradiol valerate; 
          - piperazin estriol sulfate; 
          - phytoestrogens; 
          - conjugated equine estrogens. 
 of synthesis: 
           - ethinylestradiol; 
           - mestranol; 
           - estrogen esters; 
           - non-steroidal synthesis estrogens. 
Foods with natural phytoestrogens 
Whole grains, hops, humus and soybeans, through proven health benefits, are being used increasingly in the human diet 
and can be given the name of nutritional supplement (Bădoi, D., 2012; Cardenau, H, 2010). 
Also, phytoestrogenic products from raspberries and sage leaves were consumed. 
Administration requires individualized dosing and is performed in the form of cures of at least one month, usually in 
combinations with other plants (depending on individual needs), under the strict indication and supervision of a specialist 
(Crauciuec, E., et al, 2006). 
Retrospective study. The data were selected from the observation sheets and processed using the statistical functions of 
the SPSS 18.0. 
In calculating the significant difference between two or more groups, based on the distribution of the value series, to the 
significance threshold of 95% for the quantitative variables we apply: the t-Student test– parametric test that compares 
recorded mean values in 2 groups with normal distributions; F test (ANOVA) used when three or more groups with 
normal distributions are compared; "Pearson" correlation coefficient (r) is the correlation of two variables in the same 




Structure of groups by age. Analyzing the age of the patients on the three study groups using the 
ANOVA test, the following aspects show (tab. I): 
 group I: women with natural menopause treated with Activelle, the age varied between 
40 and 62 years, with a moderate variation in the value series (9.46%); the mean age 
of the group was 51.70; 
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 group II: women with natural menopause fed natural phytoestrogens, the age varied 
between 48 and 58 years old, with the smallest variance in the range of values 
(4.94%); the mean age of the group was 51.68; 
 group III: women with natural menopause without treatment, the age varied between 
45 and 56, with a reduced range of the value series (6%); the mean age of the group 
was 52.13. 
 
Table I. Statistical indicators of the age (years) of the patients on study groups 




Min Max IC95% variance 
% 
Median  
I 51.70 4.89 0.80 40 62 49-54 9.46 52 
II 51.68 2.55 0.54 48 58 50-53 4.94 51 
III 52.13 3.13 0.64 45 56 50-55 6.0 52 
 
The distribution according to the place of origin has shown the following aspects: 
- in the groups of treated menopausal patients, the proportion of patients from rural 
areas was between 4.5 and 8.1%; 
- 29.2% of patients with untreated natural menopause originated from rural areas, 
significantly higher distribution compared to other groups. 
 
Evaluation of lipid metabolism parameters under hormonal treatment 
The clinical study aimed at evaluating the parameters of lipid metabolism and the effect of 
hormonal treatment. 
 
Total serum cholesterol (mg/dL) 
In the untreated natural menopause group, if at onset the mean cholesterol values were 
significantly lower compared to those recorded in the groups chosen for hormone treatment, at 
the end of the study the mean values were significantly higher, suggesting the beneficial effect of 
the treatment (tab. II). 
During the monitoring, mean cholesterol values showed significant differences, showing the 
beneficial effect of treatment: 
- in the group of patients with naturally occurring menopause treated with Activelle mean 
total cholesterol levels decreased significantly from mean values of 196.95 mg/dL to 
146.49 mg/dL (r= -0.99); 
- in the group of natural menopausal patients fed with natural phytoestrogens, there was a 
significant decrease in mean total cholesterol values from about 202 mg/dL to 149 mg/dL 
(r= -0.51); 
- to note that in the untreated group of patients with untreated natural menopause the 
evolution of the mean total cholesterol had an increasing trend during the monitoring, 
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Table II. Average total cholesterol (mg/dL) values per study lot/group 
Lot  monitoring time (months) 
V0 V6 V12 V24 




















The evolution of mean triglyceride values during monitoring has shown significant decreases in 
hormone-treated natural menopausal groups, highlighting the beneficial effect of treatment (tab. 
III):  
- in the group of patients with natural menopause treated with Activelle (group I), mean 
triglyceride levels decreased significantly during monitoring, from mean values of 132.10 
mg/dL to 104.59 mg/dL (r= -0.56); 
- in the group of natural menopausal patients fed with natural phytoestrogens (group II), there 
was a significant decrease in mean triglyceride levels from approximately 116 mg/dL to 
103.81 mg/dL (r= -0.63); 
- it should be noted that in the group of untreated natural menopause patients (group III) the 
evolution of the mean triglyceride values had an increasing trend during the monitoring, 
ranging from 149.20 mg/dL to 167.50 mg/dL (r= +0.77). 
 
Table III. Average triglyceride (mg/dL) values per studied group 
Lot  monitoring time (months) 
V0 V6 V12 V24 



















The fact that, regardless of the time of the study, the highest mean triglyceride values were 
observed in the untreated group, significantly higher than in the treated groups, underlines the 
importance of estrogens in the metabolism of triglycerides. 
 
LDL  cholesterol (mg/dL) 
The mean LDL cholesterol values during the study showed significant decreases (tab. IV): 
- in the group of Activelle-treated natural menopausal patients (group I) mean LDL 
cholesterol values decreased significantly from 121.86 mg/dL to 102.27 mg/dL (r = -
0.63); 
- in the group of natural menopausal patients fed with natural phytoestrogens (group II) 
there was a significant decrease in mean LDL cholesterol from 126.95 mg/dL to 95,91 
mg/dL (r= -0.89); 
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- it should be noted that in the batch of untreated natural menopause patients (group III) 
the evolution of mean LDL cholesterol had an increasing trend, ranging from 91.67 
mg/dL to 117.08 mg/dL (r= +0.83). 
 
Table  IV. Mean LDL cholesterol (mg/dL) values per studied group 
Lot  monitoring time (months) 
V0 V6 V12 V24 










95.91 ± 24.23 







At the start of the study, in the untreated natural menopausal group, the mean LDL cholesterol 
levels were significantly lower compared to those of the groups chosen for hormone therapy or 
phytoestrogens.  
At the end of the study, mean LDL cholesterol values were significantly higher in the untreated 
group. 
These results show that, due to lack of estrogen in menopause, hypercholesterolemia is an 
atherogenic risk factor. 
 
HDL cholesterol (mg/dL) 
In hormone treatment groups, during the monitoring, mean HDL cholesterol values showed 
significant increases (tab. V): 
- in the group of Activelle-treated natural menopausal patients (group I) mean values of 
HDL cholesterol significantly increased from 54.20 mg/dL to 71.41 mg/dL (r = 
+0.96); 
- in the group of natural menopausal patients treated with natural phytoestrogens (group 
II) there was a significant increase in mean HDL cholesterol values from 57.36 mg/dL 
to 69.91 mg/dL (r= +0.81); 
- it should be noted that in the group of untreated natural menopausal patients (group 
III) the evolution of mean HDL cholesterol had a decreasing trend during the 
monitoring, ranging from 44.17 mg/dL to 41.08 mg/dL (r = -0.66), which shows the 
lack of protective effect of estrogen in this context. 
 
Table V. Mean values of HDL cholesterol (mg/dL) per studied group 
Lot  monitoring time (months) 
V0 V6 V12 V24 
I 54.20 ± 17.60 58.95 ± 14.40 65.84 ± 11.93 71.41 ± 11.80 
II 57.36 ± 19.66 63.45 ± 16.57 66.41 ± 12.17 69.91 ± 8.96 
III 44.17 ± 6.02 46.04 ± 7.94 43.92 ± 7.95 41.08 ± 8.04 
 
Other biochemical parameters 
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À jéun glycemia (mg/dL) 
The glycemic values determined on study groups show the following (tab. VI): 
- the mean glycemia levels were initially significantly higher in group II (treated with 
phytoestrogens) (101.68 mg/dL) compared to the other groups; 
- after 6 months of treatment, the mean values of glycemia were significantly more 
reduced for the group treated with Activelle (group I) (90.95 mg/dL);   
- after 12 months of treatment, the mean values of glycemia were significantly 
increased for the group with natural menopause without treatment (group III) (101.33 
mg/dL) when compared with the other groups; 
- 2 years post-treatment the highest mean blood glucose levels are found in patients with 
natural menopause without treatment 103.08 mg/dL). 
 
Table VI. Mean values of glycemia (mg/dL) on studied groups 
Lot  monitoring time (months) 
V0 V6 V12 V24 
I 90.67 ± 19.54 90.95 ± 7.69 91.03 ± 5.44 90.08 ± 5.30 
II 101.68 ± 10.75 94.51 ± 5.73 92.00 ± 6.13 91.18 ± 5.18 
III 93.38 ± 4.48 96.71 ± 7.30 101.33 ± 
10.98 
103.08 ± 8.16 
 
The evolution of the mean values of glycemia showed the following aspects:  
- for the group of patients with natural menopause treated with Activelle, the mean 
values of glycemia decreased slightly during monitoring (r= -0.17); 
- for the group of patients with natural menopause fed naturally with phytoestrogens 
there was a significant decrease in mean glycemia levels (r= -0.64); 
- it is noted that in the group of menopausal patients without a hormone treatment, there 
was a significant increase in mean blood glucose levels after 2 years (r= +0.76). 
  
TGP (UI/L) 
The following must be noted about the studied groups, regardless of the moment of studying (tab. 
VII): 
- the highest mean values of TGP can be found in the group without treatment (group III); 
- for the groups following treatment, the highest mean values of TGP can be found in the 
patients treated with Activelle (group I). 
 
 
Table VII.Mean values of TGP (UI/L) on studied groups 
Lot  monitoring time (months) 
V0 V6 V12 V24 
I 23.90 ± 7.78 25.52 ± 9.21 25.70 ± 9.41 25.86 ± 8.55 
II 23.77 ± 8.45 21.55 ± 1.84 21.14 ± 1.17 21.09 ± 1.19 
III 27.71 ± 3.38 28.67 ± 3.21 28.79 ± 3.40 29.21 ± 3.45 
 
During monitoring, the groups with natural menopause with hormonal treatment, showed the 
following evolution of the mean values of TGP: 
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- for group I of patients with natural menopause, treated with Activelle, the mean 
values of TGP increased significantly, from 23.90 UI/L to 25.86 UI/L (r= +0.75); 
- for group II of patients with natural menopause treated with, the mean values of TGP 
decreased from 23.77 UI/L to 21.09 UI/L (r= -0.16); 
- the evolution of mean TGP values had an increasing trend during the monitoring, 
ranging from 27.71 UI/L to 29.21 UI/L (r= +0.73). 
 
Hemoglobin (g/dL) 
The following aspects have been found after studying the groups (tab. VIII): 
- at the start of the study, in the batch treated with synthetic or natural phytoestrogens the 
mean hemoglobin values were significantly lower than the untreated group; 
- after 12 months of treatment, mean hemoglobin values became homogeneous on the 
study groups (11.14-11.31 g/dL), which is maintained at 2 years post-treatment 
(11.09-11.26 g/dl) 
 
Table VIII. Mean hemoglobin (g/dL) values on study groups 
Lot  monitoring time (months) 
V0 V6 V12 V24 
I 11.70 ± 0.75 11.30 ± 0.77 11.26 ± 0.69 11.26 ± 0.65 
II 11.80 ± 1.09 11.40 ± 0.58 11.18 ± 0.50 11.09 ± 0.53 
III 12.00 ± 0.26 11.70 ± 0.46 11.31 ± 0.46 11.21 ± 0.41 
 
The evolution of the mean values of hemoglobin revealed the following aspects:  
- in the group of patients with natural menopause treated with Activelle, mean 
hemoglobin values decreased significantly during follow-up (r= -0.69); 
- also the group of natural menopausal patients treated with natural phytoestrogens 
showed a significant decrease in the mean values of hemoglobin (r= -0.67); 
- it should be noted, however, that also in the group of hormonal untreated menopausal 





Cholesterol is an organic alcohol, sterol that is identified in the cell membrane and body tissues 
and transported in the blood. It is concentrated in the marrow, brain and plaque of the atheroma, 
leading to atherosclerosis. 
Triglycerides are an essential component of the lipid profile, included on the list of risk factors 
for the metabolic syndrome by most current guidelines. Hypertriglyceridemia is associated with 
endothelial dysfunction and increased risk of cardiovascular disease, particularly associated with 
lowering HDL cholesterol and elevating LDL cholesterol. 
HDL cholesterol plays an important role in the metabolism of cholesterol, participating in its 
transport from extrahepatic tissues to the liver for catabolism and excretion (Hayward, C.S., et 
al., 2001). Together with LDL, it helps maintaining cellular cholesterol levels (Farhat, M.Y., et 
al., 1996; Jairath N., 2001). 
High LDL cholesterol contributes to favoring the development of endothelial dysfunction, with a 
role in the pre-lesional stage of atherosclerosis (Carl, B. & Laven A.,2007). 
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The most important studies on hormonal therapy in menopause are (ACOG, 2004): 
- the observational study Nurses Health Study (NHS) (70.000 de femei women analysed), in 
which treated women were cardiac asymptomatic and showed a lower incidence of 
cardiovascular disease and overall mortality in women under hormone therapy compared to those 
without hormone therapy. It is important to know that most women in this study started TH in 
perimenopause and had no cardiovascular disease detected at the beginning of the study. 
- HERS (The Heart and Estrogen/Progestin Replacement Study) was the first published trial of 
secondary prevention in a group of 2763 women with known cardiovascular disease, monitored 
right from the time of appearance. For an average period of time of 4.1 years there was no 
significant difference between those taking hormone therapy and placebo. There was a possible 
improvement on the longer term, but the study did not last for more than 7 years. 
- the largest randomized study is WHI (Women’s Health Initiative), which included 16,608 
women with an intact uterus who used only conjugated equine estrogens and 
medroxyprogesterone acetate as hormonal therapy versus placebo, over a period of time of 
over 5.6 years. The study was stopped earlier due to an increase in the number of cases of 
breast cancer and a lack of cardiovascular benefits in women with hormone therapy. An 
additional group of 10,739 women hysterectomized women with the same therapy, 
conjugated equine estrogens + medroxyprogesterone acetate versus placebo, was analyzed, 
showing that there are no cardiovascular benefits for these women. 
WISDOM study that was taking place in England in that period and that used the same therapy 
was interrupted after the WHI results were published. 
WHI study is considered a very important one because it changed the perception about TH, but 
this study had many limitations: the mean age of the women of 63 years old, more than 10 years 
later than the age when menopause begins, significant differences among the women taking part 
in the study, only one type pf treatment, and one administration manner. 
Thus, at the beginning of the 21st century, prescribing and using TH is still controversial, 
randomized studies (WHI, HERS) showing that estrogen may be beneficial for preventing early 
atherosclerotic lesions, but are ineffective and even harmful if the disease is installed. 
Based on the results of the randomized trials, the observational studies (PEPI, NHS) and their 
comparison showed that the relative risk of coronary artery disease increases with years of 
menopause and that in the hormone therapy-coronary / cardiovascular disease equation, the 
beginning of hormonal therapy means everything: hormone therapy should begin before the 
fibrous capsule formation of the atheromatous plaque, which was found to be between 45 and 55 
years of age; women starting hormonal therapy around menopause have a significant reduction in 
the risk of coronary artery disease (RR= 0.66 for single estrogens and 0.72 for estrogens+ 
progestative). 
Hormonal therapy is beneficial in postmenopausal women, taking into account the results 
validated over time in observational studies and is being discussed as primary prevention in cases 
without coronary artery disease at the age of 50 years under 60 years of age during the 10 years 
from the onset of menopause. For elderly women, therapy is individualized, the benefit being 
relative to the recommended age and dose. 
There is an ongoing study called KEEPS (The Kronos Early Estrogen Prevention Study) which uses 0.45 
mg conjugated equine estrogens or 50 μg transdermal estradiol in women at most 36 months after the last 
menstrual period and will show the effects on cardiovascular disease. Today there is scientific 
evidence that estrogen has effects on almost all systems and apparatuses of the female body 
(Waren, M.P., 2004). Because of this, various symptoms have been associated with decreased 
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estrogen, occurring in menopause. It is important to emphasize that not all symptoms occur to 
any woman, but there are some who encounter the highest frequency, such as vaso-motor and 
uro-genital symptoms (Peterson HB, 2004). 
Even if there is a category of symptoms that are rarely encountered, they can affect the quality of 
menopausal woman's life (Davey, D.A., 2012). 
In this study, patients treated with synthetic estrogens showed an increased frequency of hot 
flashes, migraines, asthenia, insomnia, reduced libido and vaginal dryness. Hormone therapy 
removes all these symptoms and besides the immediate improvement in the quality of life, it 
exerts a long-term protective role on the risks of osteoporotic fractures, cardiovascular disease 
and the risk of Alzheimer's disease. It is considered today that, with the exception of absolute 
contraindications and taking into account the necessary precautions in a number of general 
illnesses, 80% of women could benefit from hormone therapy. For control of menopausal 
symptoms, hormonal therapy administered for up to 5 years is appropriate, with prolongation for 
a further 5 years, if the symptom reoccurs at interruption. Hot flushes, palpitations, insomnia and 
psychological problems improve after estrogen therapy for 3 months in 90% of cases (Hudiță, D., 
et al, 2003; Christenson, E.S., et al., 2012). 
The major beneficial effects of hormonal therapy in menopause are represented by (Maki, P.M., 
et al, 2004; Gruber, C.J., 2002): 
- resolving menstrual irregularities and perimenopausal bleeding 
Continuous-combined therapy (only after histological investigation of the cause of bleeding) with 
sequential estro-progestative preparations solves the problem, effectively controlling the 
proliferation of the endometrium and restoring the regularity of menstrual cycles. Continuous-
combined TH can be recommended after a year of amenorrhea; the continuous-combined treatment 
is safe for the endometrium when it is proposed for the long term (Bodinet, C. & Freudenstein, J., 
2004).  
- the immediate, common symptoms of menopause 
There are publications that signal the results of experimental and clinical studies on the efficacy 
of phytoestrogens in the postmenopausal woman (Clarkson, T.B. et al, 2001). 
The evaluation of the effectiveness of the therapy is done clinically, asking the patient about his / 
her general condition, the persistent symptomatology or the ones appeared under therapy. 
Clinical evaluation shows evidence of underdosage or overdose, which should be noted in the 
patient's follow-up sheet, estrogen doses then being adjusted according to the type of patient-
indicated signs (tab. IX). 
 
Table IX. Criteria for clinical assessment of estrogen tolerance 
(according to Pelinescu-Onciul D, 2001) 
 Signs of underdosing Signs of overdosing 
- persistence or recurrence of heat waves - mastodynia 
- vaginal dryness - weight gain 
- asthenia - abdominal bloating 
- headache - "heavy" lower limbs 
- feeling cold - nervousness, irritability, insomnia 
- lack of tone, depression  
- joint pain  
- urinary disorders  
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Based on the cases studied, the epidemiological characteristics revealed a slightly higher mean 
age of the patients treated with synthetic or natural phytoestrogens, coming predominantly from 
cities or towns, married and with an average educational status.  
The patients started therapy in less than 5 years after the onset of menopause, thus respecting the 
"window of opportunity". 
The moment they started treatment was around the age of 50. 
Patients fed with natural phytoestrogen had a normal weight, while patients treated with synthetic 
estrogens were overweight. 
Treatment with estrogen, synthetic or natural, has resulted in an improvement in the onset 
symptoms: hot flushes, migraines, asthenia, reduced libido, insomnia and vaginal dryness. 
The climacteric symptomatology resolved under treatment. 
In patients with natural menopause, hypercholesterolemia is an atherogenic risk factor due to 
estrogen deficiency. 
The highest mean triglyceride values are noted in the untreated group, which shows the 
importance of estrogens in triglyceride metabolism. 
Patients with natural menopause, whether or not treated with estrogen, recorded significant 
decreases in mean hemoglobin level. 
Under hormonal treatment, changes in lipid profile have been achieved with a cardiovascular 
protective role, by the antiatherogenic effect of lowering total serum cholesterol, triglycerides 
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